The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .
Patients must have the ability to understand and sign an approved informed consent form (ICF).
Age at the time of consent ≥ 18 years;
Life expectancy of ≥ 3 months;
For prostate adenocarcinoma, at least one evaluable lesion by RECIST v1.1 and PCWG3 criteria; for other advanced solid tumor, at least one measurable lesion by RECIST v1.1 criteria.
Any previous treatment with a PARG inhibitor.
Subjects known to be allergic to the study drug or its active ingredients or excipients;
Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose; or received palliative radiotherapy within 2 weeks before the first dose;
Subjects who participated in any other clinical trial of anti-tumor therapy within 28 days before the first dosing, and the last dose of other anti-tumor trial drug is within 28 days prior to the first administration of study drug in this trial;
Evopoint Biosciences Inc.
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator